Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1–34

Mice heterozygous for targeted disruption of Pthrp exhibit, by 3 months of age, diminished bone volume and skeletal microarchitectural changes indicative of advanced osteoporosis. Impaired bone formation arising from decreased BM precursor cell recruitment and increased apoptotic death of osteoblast...

Full description

Saved in:
Bibliographic Details
Main Authors: Miao, Dengshun, He, Bin, Jiang, Yebin, Kobayashi, Tatsuya, Sorocéanu, Maria A., Zhao, Jenny, Su, Hanyi, Tong, Xinkang, Amizuka, Norio, Gupta, Ajay, Genant, Harry K., Kronenberg, Henry M., Goltzman, David, Karaplis, Andrew C.
Format: Artigo
Language:Inglês
Published: American Society for Clinical Investigation 2005
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC1193882/
https://ncbi.nlm.nih.gov/pubmed/16138191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI24918
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items